查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1763961

活性藥物成分市場－全球產業規模、佔有率、趨勢、機會和預測（按合成類型、應用、地區和競爭細分，2020-2030 年）

Active Pharmaceutical Ingredient Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Synthesis, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球活性藥物成分 (API) 市值為1,554.1億美元，預計2030年將達到2,276.7億美元，預測期內複合年成長率為6.77%。隨著製藥公司不斷拓展其治療產品組合，以應對包括腫瘤、心血管疾病、神經系統疾病、糖尿病和呼吸系統疾病在內的一系列疾病，對API的需求正在穩步成長。這種激增主要是由於全球慢性病負擔日益加重、人口老化以及生活方式的改變。

市場概覽
預測期 2026-2030
2024年市場規模 1554.1億美元
2030年市場規模 2276.7億美元
2025-2030 年複合年成長率 6.77%
成長最快的領域 生物技術
最大的市場 北美洲

市場格局正受到日益嚴格的監管審查的影響，監管重點集中在良好生產規範 (GMP) 和嚴格的品質控制標準。 API 製造商正透過投資先進技術、改進流程自動化和優先考慮環境永續性來應對這項挑戰。隨著全球供應鏈的不斷多元化，對於尋求保持競爭力並滿足製藥業動態需求的製造商而言，在法規合規性、基礎設施和地理適應性方面的策略性投資仍將至關重要。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

生產成本高

主要市場趨勢

胜肽和寡核苷酸 API 的興起

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球活性藥物成分市場的影響

第5章：全球活性藥物成分市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依合成類型（生物技術、發酵、植物萃取、合成）
    • 按應用（心血管疾病、腫瘤學、神經系統疾病、骨科疾病、呼吸系統疾病、胃腸道疾病、泌尿科、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美活性藥物成分市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲活性藥物成分市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區活性藥物成分市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美活性藥物成分市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲活性藥物成分市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球活性藥物成分市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Sanofi SA
  • Eli Lilly and Company
  • AbbVie Inc

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 5062

The Global Active Pharmaceutical Ingredient (API) Market was valued at USD 155.41 Billion in 2024 and is projected to reach USD 227.67 Billion by 2030, growing at a CAGR of 6.77% during the forecast period. Demand for APIs is rising steadily as pharmaceutical companies broaden their therapeutic portfolios to address a wide array of conditions including oncology, cardiovascular ailments, neurological disorders, diabetes, and respiratory diseases. This surge is largely driven by the growing global burden of chronic illnesses, an aging population, and evolving lifestyle factors.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 155.41 Billion
Market Size 2030USD 227.67 Billion
CAGR 2025-20306.77%
Fastest Growing SegmentBiotech
Largest MarketNorth America

The market landscape is being shaped by increasing regulatory scrutiny focused on Good Manufacturing Practices (GMP) and stringent quality control standards. API manufacturers are responding by investing in advanced technologies, improving process automation, and prioritizing environmental sustainability. As global supply chains continue to diversify, strategic investment in regulatory compliance, infrastructure, and geographic resilience will remain essential for manufacturers seeking to maintain competitiveness and meet the dynamic needs of the pharmaceutical sector.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare sector is a primary catalyst for growth in the API market. With healthcare spending exceeding USD 4 trillion annually, pharmaceuticals and biotechnology account for a significant portion-over USD 850 billion-underscoring the vital role APIs play in medical innovation and treatment delivery.

The escalating prevalence of chronic conditions such as cardiovascular diseases, cancer, and diabetes has led to a sharp increase in demand for high-quality, effective APIs. In 2021, noncommunicable diseases (NCDs) accounted for around 43 million deaths worldwide, representing approximately 75% of all non-pandemic-related fatalities. These health burdens drive the need for long-term medication use, prompting pharmaceutical companies to ramp up API production to meet growing therapeutic demands. The development of biologics and high-potency APIs (HPAPIs) further reflects the healthcare sector's focus on targeted, personalized treatments, reinforcing sustained market growth.

Key Market Challenges

High Cost of Production

High production costs present a substantial barrier in the global API market, affecting both manufacturer margins and the affordability of end products. These costs stem from intricate synthesis procedures, rigorous quality and safety requirements, and the rising expense of sourcing raw materials.

Complying with Good Manufacturing Practices (GMP) mandates the use of highly specialized equipment, skilled personnel, and continuous quality assurance efforts, significantly elevating both capital and operational expenditures-particularly in developed markets. Additionally, maintaining consistent output quality, ensuring regulatory compliance, and managing environmentally sustainable operations add further financial strain. This economic burden restricts entry for smaller firms and contributes to price volatility, especially in regions with limited manufacturing infrastructure.

Key Market Trends

Rise of Peptide and Oligonucleotide APIs

A prominent trend shaping the API market is the surge in demand for peptide and oligonucleotide APIs, driven by the global push toward precision medicine and biologically targeted therapies. GLP-1 analogs like semaglutide and liraglutide are gaining attention in the generics segment, particularly for their effectiveness in treating diabetes and obesity.

Peptides, with their high specificity and minimal toxicity, are increasingly used in treating cancers and metabolic or rare genetic disorders. Likewise, oligonucleotide APIs, composed of DNA or RNA sequences, allow for therapeutic targeting at the genetic level, opening new treatment avenues for diseases previously considered intractable. These innovations support the pharmaceutical industry's pivot to high-efficacy treatments, marking a shift from conventional small-molecule drugs to advanced, biologically complex APIs.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Sanofi S.A.
  • Eli Lilly and Company
  • AbbVie Inc

Report Scope

In this report, the Global Active Pharmaceutical Ingredient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredient Market, By Type of Synthesis:

  • Biotech
  • Fermentation
  • Plant Extracts
  • Synthetic

Active Pharmaceutical Ingredient Market, By Application:

  • Cardiovascular Disease
  • Oncology
  • Neurological Disorders
  • Orthopedic Disorders
  • Respiratory
  • Gastrointestinal Disorders
  • Urology
  • Others

Active Pharmaceutical Ingredient Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredient Market.

Available Customizations

Global Active Pharmaceutical Ingredient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Active Pharmaceutical Ingredient Market

5. Global Active Pharmaceutical Ingredient Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Synthesis (Biotech, Fermentation, Plant Extracts, Synthetic)
    • 5.2.2. By Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Active Pharmaceutical Ingredient Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Synthesis
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Active Pharmaceutical Ingredient Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Synthesis
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Active Pharmaceutical Ingredient Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Synthesis
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Active Pharmaceutical Ingredient Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Synthesis
        • 6.3.3.2.2. By Application

7. Europe Active Pharmaceutical Ingredient Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Synthesis
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Active Pharmaceutical Ingredient Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Synthesis
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Active Pharmaceutical Ingredient Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Synthesis
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Active Pharmaceutical Ingredient Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Synthesis
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Active Pharmaceutical Ingredient Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Synthesis
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Active Pharmaceutical Ingredient Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Synthesis
        • 7.3.5.2.2. By Application

8. Asia Pacific Active Pharmaceutical Ingredient Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Synthesis
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Active Pharmaceutical Ingredient Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Synthesis
        • 8.3.1.2.2. By Application
    • 8.3.2. India Active Pharmaceutical Ingredient Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Synthesis
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Active Pharmaceutical Ingredient Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Synthesis
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Active Pharmaceutical Ingredient Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Synthesis
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Active Pharmaceutical Ingredient Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Synthesis
        • 8.3.5.2.2. By Application

9. South America Active Pharmaceutical Ingredient Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Synthesis
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Active Pharmaceutical Ingredient Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Synthesis
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Active Pharmaceutical Ingredient Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Synthesis
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Active Pharmaceutical Ingredient Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Synthesis
        • 9.3.3.2.2. By Application

10. Middle East and Africa Active Pharmaceutical Ingredient Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Synthesis
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Active Pharmaceutical Ingredient Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Synthesis
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredient Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Synthesis
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Active Pharmaceutical Ingredient Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Synthesis
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Active Pharmaceutical Ingredient Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Teva Pharmaceutical Industries Ltd.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Boehringer Ingelheim GmbH
  • 16.4. Merck & Co., Inc.
  • 16.5. GlaxoSmithKline Plc
  • 16.6. Novartis International AG
  • 16.7. F. Hoffmann-La Roche AG
  • 16.8. Sanofi S.A.
  • 16.9. Eli Lilly and Company
  • 16.10. AbbVie Inc

17. Strategic Recommendations

18. About Us & Disclaimer